# SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

> **NCT03982381** · PHASE4 · COMPLETED · sponsor: **Uppsala University** · enrollment: 2067 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Metformin
- **DRUG:** Dapagliflozin 10 MG

## Key facts

- **NCT ID:** NCT03982381
- **Lead sponsor:** Uppsala University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-05
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 2067 (ACTUAL)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982381, "SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03982381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*